BioSpace News Archive

Proscia®, a leading provider of digital and computational pathology solutions, today announced that Laboratorium Pathologie Oost-Nederland (LabPON), the first laboratory in the world to reach 100% digital pathology diagnosis, will deploy its Concentriq® platform.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

Eisai will present five abstracts across four tumor types at the Gastrointestinal Cancers Symposium (#GI21), which is being held virtually from January 15-17, 2021.

Resolution Bioscience, Inc. today announced a companion diagnostic agreement with Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company.

Establishment Labs Holdings Inc., a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, reported preliminary revenue and cash figures for the fourth quarter and fiscal year ended December 31, 2020.

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors has formed a strategic review committee with a view to enhancing shareholder value

Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PVSRIPO for the treatment of advanced melanoma (stage IIB-IV)

ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that David Lockhart, CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:30 p.m. ET on Wednesday, January 13, 2021.

Phyton Biotech today announced that it has established high-yielding plant cell lines of Veratum californicum, the source of cyclopamine, a key raw material for PellePharm’s patedigib topical gel, an investigational treatment to be used for rare dermatologic conditions.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities.